A crosslinked biobased hydrophilic foam comprising a reaction product of: a cleaned biobased polyoxyalkylene glycol polyol with an ethylene oxide content of at least 40 mole percent, constituting 31.80 to 67.95 percent biogenic carbon content by weight, constituting less than 15 ppm combined sodium and potassium metals, and comprising less than 0.5% water by weight; an isocyanate, wherein the isocyanate and the cleaned biobased polyoxyalkylene glycol polyol are premixed to create a prepolymer mixture with the cleaned biobased polyoxyalkylene glycol polyol of the prepolymer mixture; and water, wherein the water is admixed with the prepolymer mixture to yield the crosslinked biobased hydrophilic foam.

A crosslinked biobased hydrophilic foam comprising a reaction product of: a cleaned biobased polyoxyalkylene glycol polyol with an ethylene oxide content of at least 40 mole percent, constituting 31.80 to 67.95 percent biogenic carbon content by weight, constituting less than 15 ppm combined sodium and potassium metals, and comprising less than 0.5% water by weight; an isocyanate, wherein the isocyanate and the cleaned biobased polyoxyalkylene glycol polyol are premixed to create a prepolymer mixture with the cleaned biobased polyoxyalkylene glycol polyol of the prepolymer mixture; and water, wherein the water is admixed with the prepolymer mixture to yield the crosslinked biobased hydrophilic foam.

A modified polycarbodiimide compound which is obtained by modifying at least some of carbodiimide groups in a polycarbodiimide derived from a diisocyanate compound, said polycarbodiimide having a terminal blocked with a hydrophilic compound, with an aromatic heterocyclic compound such as 3,5-dimethylpyrazole having endocyclic secondary amine nitrogen has a potential for a cuing agent, and exhibits the activity of the carbodiimide groups by being unblocked at relatively low temperatures.

The present invention relates to a multi-aziridine compound having: a) at least 2 of the following structural units (A) whereby R.sub.1 is H; R.sub.2 and R.sub.4 are independently chosen from H, a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; R.sub.3 is chosen from a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; or R.sub.2 and R.sub.3 (in case R.sub.2 is different than H) may be part of the same cyclic group containing from 3 to 8 carbon atoms; R′ and R″ are independently H or an aliphatic hydrocarbon group containing from 1 to 12 carbon atoms; and b) a molecular weight of at least 600 Daltons, wherein the molecular weight is determined using MALDI-TOF mass spectrometry according to the description.

The present invention relates to a multi-aziridine compound having: a) at least 2 of the following structural units (A) whereby R.sub.1 is H; R.sub.2 and R.sub.4 are independently chosen from H, a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; R.sub.3 is chosen from a linear group containing from 1 to 8 carbon atoms and optionally containing one or more heteroatoms, a branched or cyclic group containing from 3 to 8 carbon atoms and optionally containing one or more heteroatoms, phenyl, benzyl, or pyridinyl; or R.sub.2 and R.sub.3 (in case R.sub.2 is different than H) may be part of the same cyclic group containing from 3 to 8 carbon atoms; R′ and R″ are independently H or an aliphatic hydrocarbon group containing from 1 to 12 carbon atoms; and b) a molecular weight of at least 600 Daltons, wherein the molecular weight is determined using MALDI-TOF mass spectrometry according to the description.

Described is an at least partly continuous process for making polyurethane foam layers that are suitable for medical applications, in particular in wound dressings, at a high throughput rate. The described process includes a step of accelerated curing of the polyurethane foam performed at a stage of the overall curing process at which the risk of a run-away reaction is minimized.

Described is an at least partly continuous process for making polyurethane foam layers that are suitable for medical applications, in particular in wound dressings, at a high throughput rate. The described process includes a step of accelerated curing of the polyurethane foam performed at a stage of the overall curing process at which the risk of a run-away reaction is minimized.

The present disclosure relates to acid-blocked pyrrolidine catalysts for use in a polyurethane formulation. The polyurethane formulation includes the acid-blocked pyrrolidine catalyst, a compound containing an isocyanate functional group, an active hydrogen-containing compound and a halogenated olefin compound. The use of such acid-blocked pyrrolidine catalysts show surprisingly low reactivity with halogenated olefin compounds yet sufficient reactivity to catalyze polyurethane formation.

Provided herein is an additive manufacturing method of making a three-dimensional object comprising polyurea, comprising: (a) dispensing a one part (1K) dual cure resin into a stereolithography apparatus, the resin comprising or consisting essentially of a photoinitiator, a reactive blocked polyisocyanate, and optionally a polyepoxide, the reactive blocked polyisocyanate comprising the reaction product of a polyisocyanate and an amine or hydroxyl (meth)acrylate or (meth)acrylamide monomer blocking agent; (b) additively manufacturing from said resin an intermediate object comprising the light polymerization product of said reactive blocked polyisocyanate; (c) optionally cleaning said intermediate object; and (d) reacting said polymerization product in said intermediate with water to generate polyamine in situ that sequentially reacts with the remainder of the polymerization product to form urea linkages and hereby produce a three-dimensional object comprising polyurea. One part (1K) dual cure resins useful for the method are also provided.

Provided herein is an additive manufacturing method of making a three-dimensional object comprising polyurea, comprising: (a) dispensing a one part (1K) dual cure resin into a stereolithography apparatus, the resin comprising or consisting essentially of a photoinitiator, a reactive blocked polyisocyanate, and optionally a polyepoxide, the reactive blocked polyisocyanate comprising the reaction product of a polyisocyanate and an amine or hydroxyl (meth)acrylate or (meth)acrylamide monomer blocking agent; (b) additively manufacturing from said resin an intermediate object comprising the light polymerization product of said reactive blocked polyisocyanate; (c) optionally cleaning said intermediate object; and (d) reacting said polymerization product in said intermediate with water to generate polyamine in situ that sequentially reacts with the remainder of the polymerization product to form urea linkages and hereby produce a three-dimensional object comprising polyurea. One part (1K) dual cure resins useful for the method are also provided.